Mersana Therapeutics, Inc. Earns Milestone Payment in Fleximer-ADC Collaboration With Endo Pharmaceuticals

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mersana Therapeutics, Inc. announced today that it successfully achieved the first preclinical milestone in its collaboration with Endo Pharmaceuticals (Nasdaq: ENDP). In recognition of the significant progress made to date, Mersana has received an undisclosed milestone payment from Endo. In 2012, Mersana and Endo entered into a multi-target, oncology focused partnership to develop next-generation Fleximer® antibody-drug conjugates (ADCs).

Help employers find you! Check out all the jobs and post your resume.

Back to news